V Square Quantitative Management LLC Has $513,000 Stake in Sanofi (NASDAQ:SNY)

V Square Quantitative Management LLC raised its stake in shares of Sanofi (NASDAQ:SNY) by 5.3% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 10,378 shares of the company’s stock after purchasing an additional 526 shares during the period. V Square Quantitative Management LLC’s holdings in Sanofi were worth $513,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. International Assets Investment Management LLC bought a new position in shares of Sanofi during the 4th quarter worth approximately $4,704,000. Prime Capital Investment Advisors LLC bought a new position in shares of Sanofi during the 4th quarter worth approximately $201,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Sanofi by 5.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 46,350 shares of the company’s stock worth $2,305,000 after purchasing an additional 2,464 shares during the period. Cerity Partners LLC raised its holdings in shares of Sanofi by 7.6% in the 4th quarter. Cerity Partners LLC now owns 81,674 shares of the company’s stock worth $4,062,000 after purchasing an additional 5,764 shares during the period. Finally, NewEdge Wealth LLC raised its holdings in shares of Sanofi by 4.4% in the 4th quarter. NewEdge Wealth LLC now owns 22,319 shares of the company’s stock worth $1,110,000 after purchasing an additional 949 shares during the period. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Performance

Shares of NASDAQ:SNY opened at $53.76 on Thursday. The company has a market cap of $136.16 billion, a price-to-earnings ratio of 26.90, a price-to-earnings-growth ratio of 1.52 and a beta of 0.59. The company has a 50-day moving average price of $50.10 and a 200-day moving average price of $48.78. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a 12 month low of $42.63 and a 12 month high of $55.72.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.93 EPS for the quarter, beating the consensus estimate of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm had revenue of $10.75 billion during the quarter, compared to the consensus estimate of $16.86 billion. During the same period in the prior year, the firm posted $0.95 earnings per share. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. As a group, equities analysts anticipate that Sanofi will post 4.18 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday. Argus boosted their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.